TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+0.51%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.57B
AUM Growth
-$21.5M
(-0.83%)
Cap. Flow
+$30M
Cap. Flow
% of AUM
1.17%
Top 10 Holdings %
Top 10 Hldgs %
39.02%
Holding
198
New
37
Increased
49
Reduced
41
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$38.2M |
| 2 |
Johnson & Johnson
JNJ
|
$20.1M |
| 3 |
Esperion Therapeutics
ESPR
|
$13.7M |
| 4 |
Nektar Therapeutics
NKTR
|
$13.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
$11.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$34.4M |
| 2 |
Amgen
AMGN
|
$27.5M |
| 3 |
Biogen
BIIB
|
$18.3M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$17.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$16.9M |
Sector Composition
| 1 | Healthcare | 93.47% |
| 2 | Real Estate | 2.71% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
101
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.98M | 0.15% |
75,400
| – | – |
|
102
Puma Biotechnology
PBYI
$253M
| $3.81M | 0.15% |
55,985
+7,593
| +16% | +$517K |
|
103
Ovid Therapeutics
OVID
$87.5M
| $3.79M | 0.15% |
535,824
| – | – |
|
104
Becton Dickinson
BDX
$55.1B
| $3.74M | 0.15% |
+17,685
| New | +$3.74M |
|
105
Masimo
MASI
$8B
| $3.67M | 0.14% |
+41,666
| New | +$3.67M |
|
|
ALDR
106
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $3.56M | 0.14% |
+279,950
| New | +$3.56M |
|
107
Intellia Therapeutics
NTLA
$1.29B
| $3.53M | 0.14% |
+167,381
| New | +$3.53M |
|
|
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
| $3.37M | 0.13% |
468,399
+18,399
| +4% | +$132K |
|
|
AFMD
109
DELISTED
Affimed
AFMD
| $3.34M | 0.13% |
180,532
+40,000
| +28% | +$740K |
|
110
ResMed
RMD
$40.6B
| $3.33M | 0.13% |
+33,819
| New | +$3.33M |
|
|
TSRO
111
DELISTED
TESARO, Inc.
TSRO
| $3.29M | 0.13% |
57,595
| – | – |
|
112
Ardelyx
ARDX
$1.57B
| $3.23M | 0.13% |
639,370
| – | – |
|
|
MYOV
113
DELISTED
Myovant Sciences Ltd.
MYOV
| $3.2M | 0.12% |
150,471
-249,529
| -62% | -$5.31M |
|
114
argenx
ARGX
$45.9B
| $3.13M | 0.12% |
38,931
-7,535
| -16% | -$606K |
|
115
Perrigo
PRGO
$3.12B
| $3.11M | 0.12% |
37,300
| – | – |
|
116
Bausch Health
BHC
$2.72B
| $3.06M | 0.12% |
192,000
| – | – |
|
|
PTLA
117
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.94M | 0.11% |
+89,978
| New | +$2.94M |
|
118
Philips
PHG
$26.5B
| $2.89M | 0.11% |
95,695
+6,777
| +8% | +$204K |
|
119
Syndax Pharmaceuticals
SNDX
$1.47B
| $2.85M | 0.11% |
200,000
| – | – |
|
120
Innoviva
INVA
$1.29B
| $2.69M | 0.1% |
161,603
-87,200
| -35% | -$1.45M |
|
|
PRAH
121
DELISTED
PRA Health Sciences, Inc.
PRAH
| $2.69M | 0.1% |
32,460
-32,460
| -50% | -$2.69M |
|
|
TTPH
122
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $2.64M | 0.1% |
42,966
| – | – |
|
123
Baxter International
BAX
$12.5B
| $2.6M | 0.1% |
+39,965
| New | +$2.6M |
|
|
ARRY
124
DELISTED
Array Biopharma Inc
ARRY
| $2.55M | 0.1% |
+156,056
| New | +$2.55M |
|
125
Charles River Laboratories
CRL
$8.07B
| $2.42M | 0.09% |
22,670
-63,134
| -74% | -$6.74M |
|